OP02 Increased incidence of hypothyroidism in breast cancer survivors – a danish population-based matched cohort study

IntroductionBreast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors.Methods and analysisPopulation-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018.Ethics and disseminationThis study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations.Trial registration numberThis protocol is registered in Clinical Trials.gov (identifier: NCT03846999).

Download Full-text

Risk of anxiety and depression in breast cancer survivors compared to women who have never had cancer: A population-based cohort study in the United Kingdom.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.1564 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 1564-1564

Author(s):

Helena Carreira ◽

Rachael Williams ◽

Garth Funston ◽

Susannah Jane Stanway ◽

Krishnan Bhaskaran

Keyword(s):

Breast Cancer ◽

Primary Care ◽

Cohort Study ◽

United Kingdom ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Population Based ◽

Anxiety And Depression ◽

The United Kingdom ◽

History Of

1564 Background: Breast cancer survivors are the largest group of cancer survivors in the United Kingdom (UK). Having had a breast cancer diagnosis may adversely affect the patient’s mental health. We aimed to estimate the long-term risk of anxiety and depression in women with history of breast cancer compared to those who have never had cancer. Methods: We conducted a matched population-based cohort study, using data from the Clinical Practice Research Datalink (CPRD) GOLD primary care database. The exposed cohort included all adult women diagnosed with breast cancer between 1987 and 2018; the unexposed group included women with no cancer history, matched to exposed women in a 4:1 ratio on primary care practice and age. Cox regression models stratified on matched set were used to estimate hazard ratios of the association between breast cancer survivorship and anxiety and depression. Results: 59,972 women (mean 62 years; standard deviation (SD) 14.0) had history of breast cancer. The median follow-up time was 3.0 years (SD 4.4), which amounted to 256,186 person-years under observation. The comparison group included 240,387 women followed up over 3.5 years (SD 4.5) (1,163,819 person-years). The incidence of anxiety in breast cancer survivors was 0.08 (95% confidence interval (95%) 0.07-0.08) per 1000 person-years, and the incidence of depression was 70 (95%CI 68-71) per 1000 person-years. The risks of both depression and anxiety were raised in breast cancer survivors compared with controls, and this appeared to be driven by the first 3 years following diagnosis (Table). Conclusions: Breast cancer survivors in the UK had significantly higher risk anxiety and depression diagnosed in primary care for three years following diagnosis than women who never had cancer. Risk of anxiety and depression in breast cancer survivors compared to women who did not have cancer by time since diagnosis. [Table: see text]

Download Full-text

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study

BMJ Open ◽

10.1136/bmjopen-2017-019364 ◽

2018 ◽

Vol 8 (5) ◽

pp. e019364 ◽

Cited By ~ 3

Author(s):

Wen-Yen Chiou ◽

Moon-Sing Lee ◽

Shih-Kai Hung ◽

Hon-Yi Lin ◽

Yuan-Chen Lo ◽

...

Keyword(s):

Cohort Study ◽

Propensity Score ◽

Cancer Survivors ◽

Population Based ◽

Polysaccharide Vaccine ◽

Matched Cohort ◽

Pneumococcal Polysaccharide Vaccine ◽

Matched Cohort Study

Download Full-text

Risk of being granted disability pension among incident cancer patients before and after a structural pension reform: A Danish population-based, matched cohort study

Scandinavian Journal of Work Environment & Health ◽

10.5271/sjweh.3883 ◽

2020 ◽

Vol 46 (4) ◽

pp. 382-391 ◽

Cited By ~ 1

Author(s):

Pernille Pedersen ◽

Maria Aagesen ◽

Lars Hermann Tang ◽

Niels Henrik Bruun ◽

Ann-Dorthe Zwisler ◽

...

Keyword(s):

Cohort Study ◽

Cancer Patients ◽

Disability Pension ◽

Pension Reform ◽

Population Based ◽

Matched Cohort ◽

Danish Population ◽

Matched Cohort Study ◽

Incident Cancer ◽

Before And After

Download Full-text

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study

BMJ ◽

10.1136/bmj.k96 ◽

2018 ◽

pp. k96 ◽

Cited By ~ 78

Author(s):

Kasper Adelborg ◽

Szimonetta Komjáthiné Szépligeti ◽

Louise Holland-Bill ◽

Vera Ehrenstein ◽

Erzsébet Horváth-Puhó ◽

...

Keyword(s):

Cohort Study ◽

Cardiovascular Diseases ◽

Population Based ◽

Matched Cohort ◽

Danish Population ◽

Matched Cohort Study

Download Full-text

Postdiagnosis weight change is associated with poorer survival in breast cancer survivors: A prospective population‐based patient cohort study

International Journal of Cancer ◽

10.1002/ijc.33181 ◽

2020 ◽

Vol 148 (1) ◽

pp. 18-27 ◽

Cited By ~ 1

Author(s):

Audrey Y. Jung ◽

Anika Hüsing ◽

Sabine Behrens ◽

Julia Krzykalla ◽

Nadia Obi ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Cancer Survivors ◽

Weight Change ◽

Breast Cancer Survivors ◽

Population Based ◽

Patient Cohort

Download Full-text

Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan

Frontiers in Oncology ◽

10.3389/fonc.2021.756143 ◽

2021 ◽

Vol 11 ◽

Author(s):

Yin-Che Lu ◽

Pin-Tzu Chen ◽

Mei-Chen Lin ◽

Che-Chen Lin ◽

Shi-Heng Wang ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Propensity Score ◽

Cancer Risk ◽

Population Based ◽

Matched Cohort ◽

Second Cancer ◽

Matched Cohort Study ◽

Inflammatory Drugs ◽

Second Cancer Risk

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce mortality in patients with cancer, especially breast cancer, but their influence on second cancer risk is uncertain. This study aimed to examine whether NSAID use is associated with second cancer risk in patients with breast cancer. This population-based propensity score-matched cohort study using Taiwan’s National Health Insurance Research Database enrolled patients with newly diagnosed breast cancer (n = 7356) with and without (n = 1839) NSAID therapy from 2000 to 2009. They were followed up until the diagnosis of second cancer, death, or end of 2011. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR). The NSAID cohort had a lower incidence rate of second cancer than the non-NSAID cohort (5.57 vs. 9.19 per 1,000 person-years), with an aHR of 0.63 (95% confidence interval (CI) 0.46–0.87). When compared with the non-NSAID cohort, the second cancer incidence was lower in patients taking non-cyclooxygenase 2 inhibitors (aHR 0.67, 95% CI 0.47–0.94) and in those receiving multiple NSAIDs during follow-up (aHR 0.55, 95% CI 0.37–0.84). A dose–response relationship existed in NSAID cumulative days. The findings demonstrate that NSAID use reduces second cancer risk in a dose-dependent manner in patients with primary breast cancer.

Download Full-text